🇺🇸 FDA
Pipeline program

OPB-51602

NP01/27/13

Phase 1 small_molecule terminated

Quick answer

OPB-51602 for Nasopharyngeal Carcinoma is a Phase 1 program (small_molecule) at Hospital Authority, Hong Kong with 1 ClinicalTrials.gov record(s).

Program details

Company
Hospital Authority, Hong Kong
Indication
Nasopharyngeal Carcinoma
Phase
Phase 1
Modality
small_molecule
Status
terminated

Clinical trials